vs
Clearfield, Inc.（CLFD）与STANDARD BIOTOOLS INC.（LAB）财务数据对比。点击上方公司名可切换其他公司
Clearfield, Inc.的季度营收约是STANDARD BIOTOOLS INC.的1.8倍（$34.3M vs $19.6M），Clearfield, Inc.净利率更高（-1.8% vs -177.4%，领先175.6%），Clearfield, Inc.同比增速更快（-3.2% vs -11.5%），Clearfield, Inc.自由现金流更多（$-2.4M vs $-23.1M），过去两年Clearfield, Inc.的营收复合增速更高（-3.5% vs -12.2%）
Clearfield, Inc.总部位于美国明尼苏达州明尼阿波利斯市，是一家专注于光纤产品研发生产的企业，其产品主要应用于光纤通信网络建设领域，为通信基础设施部署提供相关硬件支撑。
Standard BioTools（原Fluidigm公司）是一家美国生命科学工具企业，主营流式细胞术与组织成像分析用质谱流式系统，以及配套的检测试剂盒与试剂，同时供应自动化基因组分析仪器、各类微流控芯片（又称集成流体电路）及配套试剂耗材，全系列产品及应用场景均可提供定制检测方案与相关服务。
CLFD vs LAB — 直观对比
营收规模更大
CLFD
是对方的1.8倍
$19.6M
营收增速更快
CLFD
高出8.3%
-11.5%
净利率更高
CLFD
高出175.6%
-177.4%
自由现金流更多
CLFD
多$20.7M
$-23.1M
两年增速更快
CLFD
近两年复合增速
-12.2%
损益表 — Q1 FY2026 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $34.3M | $19.6M |
| 净利润 | $-614.0K | $-34.7M |
| 毛利率 | 33.2% | 48.5% |
| 营业利润率 | -5.3% | -168.5% |
| 净利率 | -1.8% | -177.4% |
| 营收同比 | -3.2% | -11.5% |
| 净利润同比 | 67.8% | -28.8% |
| 每股收益（稀释后） | $-0.04 | $-0.09 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLFDLAB
| Q4 25 | $34.3M | — | ||
| Q3 25 | $23.4M | $19.6M | ||
| Q2 25 | $49.9M | $21.8M | ||
| Q1 25 | $47.2M | $40.8M | ||
| Q4 24 | $29.7M | — | ||
| Q3 24 | $5.6M | $22.1M | ||
| Q2 24 | $48.8M | $22.5M | ||
| Q1 24 | $36.9M | $45.5M |
净利润CLFDLAB
| Q4 25 | $-614.0K | — | ||
| Q3 25 | $-9.1M | $-34.7M | ||
| Q2 25 | $1.6M | $-33.5M | ||
| Q1 25 | $1.3M | $-26.0M | ||
| Q4 24 | $-1.9M | — | ||
| Q3 24 | — | $-26.9M | ||
| Q2 24 | $-447.0K | $-45.7M | ||
| Q1 24 | $-5.9M | $-32.2M |
毛利率CLFDLAB
| Q4 25 | 33.2% | — | ||
| Q3 25 | 53.2% | 48.5% | ||
| Q2 25 | 30.5% | 48.8% | ||
| Q1 25 | 30.1% | 48.4% | ||
| Q4 24 | 29.2% | — | ||
| Q3 24 | — | 54.9% | ||
| Q2 24 | 21.9% | 46.1% | ||
| Q1 24 | 7.7% | 53.1% |
营业利润率CLFDLAB
| Q4 25 | -5.3% | — | ||
| Q3 25 | 10.3% | -168.5% | ||
| Q2 25 | 3.0% | -118.1% | ||
| Q1 25 | 0.6% | -80.8% | ||
| Q4 24 | -6.9% | — | ||
| Q3 24 | — | -120.9% | ||
| Q2 24 | -4.7% | -134.5% | ||
| Q1 24 | -26.4% | -132.2% |
净利率CLFDLAB
| Q4 25 | -1.8% | — | ||
| Q3 25 | -38.8% | -177.4% | ||
| Q2 25 | 3.2% | -153.7% | ||
| Q1 25 | 2.8% | -63.8% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | — | -122.0% | ||
| Q2 24 | -0.9% | -203.3% | ||
| Q1 24 | -16.0% | -70.6% |
每股收益（稀释后）CLFDLAB
| Q4 25 | $-0.04 | — | ||
| Q3 25 | $-0.65 | $-0.09 | ||
| Q2 25 | $0.11 | $-0.09 | ||
| Q1 25 | $0.09 | $-0.07 | ||
| Q4 24 | $-0.13 | — | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | $-0.04 | $-0.12 | ||
| Q1 24 | $-0.40 | $-0.27 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $96.4M | $129.4M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $249.7M | $399.7M |
| 总资产 | $268.1M | $539.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLFDLAB
| Q4 25 | $96.4M | — | ||
| Q3 25 | $106.0M | $129.4M | ||
| Q2 25 | $117.2M | $158.6M | ||
| Q1 25 | $112.0M | $150.9M | ||
| Q4 24 | $113.0M | — | ||
| Q3 24 | $129.0M | $210.6M | ||
| Q2 24 | $123.8M | $269.8M | ||
| Q1 24 | $142.9M | $287.1M |
总债务CLFDLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $2.2M | $55.2M | ||
| Q2 24 | $2.1M | $55.1M | ||
| Q1 24 | — | $55.0M |
股东权益CLFDLAB
| Q4 25 | $249.7M | — | ||
| Q3 25 | $256.2M | $399.7M | ||
| Q2 25 | $264.5M | $424.5M | ||
| Q1 25 | $265.9M | $454.6M | ||
| Q4 24 | $267.4M | — | ||
| Q3 24 | $275.8M | $489.3M | ||
| Q2 24 | $274.6M | $510.3M | ||
| Q1 24 | $279.2M | $577.3M |
总资产CLFDLAB
| Q4 25 | $268.1M | — | ||
| Q3 25 | $306.2M | $539.6M | ||
| Q2 25 | $314.7M | $557.0M | ||
| Q1 25 | $310.9M | $579.6M | ||
| Q4 24 | $303.2M | — | ||
| Q3 24 | $315.3M | $681.5M | ||
| Q2 24 | $318.1M | $708.7M | ||
| Q1 24 | $315.4M | $777.7M |
负债/权益比CLFDLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.01× | 0.11× | ||
| Q2 24 | 0.01× | 0.11× | ||
| Q1 24 | — | 0.10× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-1.4M | $-22.2M |
| 自由现金流经营现金流 - 资本支出 | $-2.4M | $-23.1M |
| 自由现金流率自由现金流/营收 | -7.1% | -118.1% |
| 资本支出强度资本支出/营收 | 2.9% | 4.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-111.1M |
8季度趋势，按日历期对齐
经营现金流CLFDLAB
| Q4 25 | $-1.4M | — | ||
| Q3 25 | — | $-22.2M | ||
| Q2 25 | $7.9M | $-20.7M | ||
| Q1 25 | $3.0M | $-30.3M | ||
| Q4 24 | $7.2M | — | ||
| Q3 24 | $22.2M | $-27.9M | ||
| Q2 24 | $4.0M | $-39.0M | ||
| Q1 24 | $-5.7M | $-62.5M |
自由现金流CLFDLAB
| Q4 25 | $-2.4M | — | ||
| Q3 25 | — | $-23.1M | ||
| Q2 25 | $7.5M | $-22.6M | ||
| Q1 25 | $654.0K | $-35.3M | ||
| Q4 24 | $5.1M | — | ||
| Q3 24 | $18.2M | $-30.1M | ||
| Q2 24 | $2.8M | $-41.0M | ||
| Q1 24 | $-7.7M | $-63.3M |
自由现金流率CLFDLAB
| Q4 25 | -7.1% | — | ||
| Q3 25 | — | -118.1% | ||
| Q2 25 | 15.1% | -103.6% | ||
| Q1 25 | 1.4% | -86.6% | ||
| Q4 24 | 17.1% | — | ||
| Q3 24 | 323.0% | -136.4% | ||
| Q2 24 | 5.8% | -182.2% | ||
| Q1 24 | -20.8% | -138.9% |
资本支出强度CLFDLAB
| Q4 25 | 2.9% | — | ||
| Q3 25 | 2.0% | 4.5% | ||
| Q2 25 | 0.8% | 8.7% | ||
| Q1 25 | 5.1% | 12.4% | ||
| Q4 24 | 7.0% | — | ||
| Q3 24 | 71.4% | 10.2% | ||
| Q2 24 | 2.5% | 8.6% | ||
| Q1 24 | 5.3% | 1.7% |
现金转化率CLFDLAB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.93× | — | ||
| Q1 25 | 2.30× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLFD
暂无分部数据
LAB
| Consumables | $8.7M | 45% |
| Services And Other Revenue | $5.8M | 29% |
| Instruments | $5.1M | 26% |
